Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.

Biosimilars China

Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

Launches Strategy

Amneal Takes Control Of AvKARE In US

Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”

Deals Strategy

Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

Biosimilars United States

Krka Sets Out Strategy In Multiple Markets

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

Business Strategies Strategy

Cadila Healthcare Merges Four Subsidiaries

India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.

Business Strategies Strategy
See All
UsernamePublicRestriction

Register